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2Abstract 
Hyperthermia has been suggested as a novel, minimally invasive cancer treatment 
method. After implantation of magnetic nano- or microparticles around a tumor, 
irradiation with alternating magnetic fields facilitates the efficient creation of in situ 
hyperthermia for deep-seated tumors. Building on this idea, if the microspheres are 
capable of delivering drugs, they could be promising multifunctional biomaterials 
effective for hyperthermia as well as chemotherapy. In the present study, magnetite 
microspheres were prepared using emulsion methods. The release behavior of 
alendronate, a typical bisphosphonate, from the microspheres was examined in vitro as a 
model of the bone tumor prevention and treatment system. Prevention of tumor 
metastasis to bone tissues is an urgent issue because it often leads to a significant 
reduction in patient survival rates. Porous magnetite microspheres around 30 µm in 
diameter were obtained without calcination. They maintained their original spherical 
shapes even after shaking in ultrapure water for 3 days, suggesting that they have 
sufficient mechanical integrity for clinical use. The microspheres showed slow release 
of the alendronate in vitro. The release rate was well controlled by the alendronate 
concentration. 
Keywords: microspheres; drug delivery/release; alendronate; tumor; magnetite 
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3Introduction 
Hyperthermia is a minimally invasive cancer treatment that is based on the finding 
that cancer cells have lower heat resistivity than normal cells.[1] Tumors can be heated 
using several techniques such as infrared radiation, radiofrequency ablation, and using 
hot water. However, tumors located deep inside the body cannot be effectively treated 
with these techniques because their applications are external; the tumor is heated from 
outside the body. 
Therefore, novel cancer treatments using ferromagnetic ceramic particles such as 
magnetite (Fe3O4) and γ-hematite (Fe2O3) may be useful. Even deep-seated tumors can 
be effectively heated and killed if particles are implanted around them and an 
alternating magnetic field is applied from outside the body. Various magnetic 
nanoparticles have been investigated as thermoseeds for this process.[2, 3] Implantation 
of ferromagnetic microspheres of 20–30 µm diameter into blood vessels around tumors 
facilitates the induction of more efficient hyperthermia combined with embolization to 
cut off the nutrient supply to the tumors.[4–7] This type of embolization therapy is 
especially effective for liver and kidney cancers.[8] 
If these microspheres are also capable of delivering drugs, they could be 
promising multifunctional biomaterials effective for both hyperthermia and 
chemotherapy. Alendronate, a typical bisphosphonate, was chosen as a characteristic 
drug in the present study. It is clinically used for bone tumor treatment and inhibition of 
osteoporosis.[9, 10] Prevention of tumor metastasis to bone tissues is an urgent issue 
because it often leads significant reduction in patient survival rates. Although oral 
administration is widely used to deliver alendronate, there are several drawbacks to this 
method such as low biological availability (less than 1%) and side effects due to excess 
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4dosages.[11] Therefore, the development of a local and sustainable drug delivery system 
is needed to address these limitations. While the preparation of bisphosphonate-modified 
magnetite nanoparticles has been previously reported,[12] those particles were designed 
for adsorption and removal of toxic uranyl ions from blood. The release behavior of 
bisphosphonate from these nanoparticles has not yet been reported. 
In this study, magnetite microspheres were prepared using emulsion methods. 
Alendronate was incorporated into microspheres and its release was quantitatively 
assessed as a model of bone tumor prevention and treatment. 
Materials and Methods 
Preparation of microspheres
All the chemical reagents were purchased from Wako Pure Chemical Industries, 
Ltd., Japan. An aqueous volume of 37.5 mL of 37 mM FeCl2 and 49 mM FeCl3 was 
mixed with 8 mL of 26 wt% NH3 solution. The precipitate that formed was collected by 
centrifugation, washed with ultrapure water, and dispersed in 22.5 mL of 0.2 M HCl. 
The solution was then heated at 80°C for 3 hours to form a sol. A water-in-oil (W/O) 
emulsion was then obtained by mixing 2-ethyl-1-hexanol containing 3 wt% Span80 and 
the sol at weight ratio of 3:1 at a rotation speed of 3400 rpm. A precipitate was 
immediately formed by addition of the emulsion to 1-butanol. Further details of this 
preparation technique and mechanism of the microsphere formation were described 
previously.[6] 
The microstructure of the microspheres was evaluated by scanning electron 
microscopy (SEM; S-3500N, Hitachi Co., Tokyo, Japan), X-ray diffraction (XRD; 
MXP3V, Mac Science Ltd., Yokohama, Japan), and Brunauer, Emmett, and Teller 
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5(BET) surface area and pore size analyzer (Autosorb-1C/MS, Quantachrome Instruments, 
Boynton Beach, FL, USA). A thin film of Au-Pd was deposited on the surfaces of the 
specimens using an ion sputter coater (E-101, Hitachi Co., Tokyo, Japan) for SEM 
observations. To evaluate mechanical properties, 10 mg of the microspheres was soaked 
in 30 mL of ultrapure water and shaken in a water bath (H-10, Taitec Co., Koshigaya, 
Japan) at a speed of 100 strokes/min for 3 days. Morphological changes in the 
microspheres were then observed by SEM. 
In vitro drug release profiles 
A mass of 30 mg of the prepared microspheres was soaked in 20 mL of sodium 
alendronate trihydrate (NH2(CH2)3COH(PO3H2)(PO3HNa)·3H2O) solution at various 
concentrations for 1 hour under vacuum at 0.03 MPa, gently washed with ultrapure 
water, and dried at 60°C. Next, 10 mg of the drug-loaded microspheres was soaked in 
20 mL of ultrapure water at room temperature for various times. The alendronate 
concentration was quantitatively determined by inductively coupled plasma atomic 
emission spectroscopy (Optima 4300DV Cyclon, Perkin-Elmer Co., Cambridge, UK). 
Results 
Figure 1 shows an SEM image of the prepared microspheres. Porous 
microspheres with a diameter of approximately 30-40 µm were obtained. The XRD 
pattern of the microspheres is shown in Figure 2. Broad diffraction peaks assigned to 
the magnetite (JCPDS#19-0629) were detected at 30, 35, 43, 54, 58, and 63° in 2θ. The 
BET surface area was 82.3 m
2
/g and the average pore diameter was 17.6 nm.
Figure 3 shows an SEM photograph of the prepared microspheres after being 
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6shaken in ultrapure water for 3 days. Their original spherical shapes were well 
maintained even after the shaking. 
Figure 4 shows the content of alendronate incorporated into the microspheres as a 
function of the solution alendronate concentration. The incorporated mass increased 
with the increasing alendronate concentration in solution. 
Figure 5 shows the alendronate released from drug-loaded microspheres into 
ultrapure water over time as a function of the initial alendronate concentration. The 
microspheres with initial concentrations of 100 and 1000 ppm gradually released 
alendronate over time. The degree of alendronate release increased with increasing 
initial alendronate concentration. The released concentration was plotted as a function 
of the square root of soaking time (Fig. 6) showing highly linear correlations for the 100 
and 1000 ppm concentration samples. These results indicate that the process of 
alendronate release is diffusion-controlled. 
Discussion 
Magnetite microspheres were prepared by dehydration of a W/O emulsion 
containing the magnetite sol derived from Fe
2+
 and Fe
3+
. In a prior study by the present
authors, non-magnetic microspheres of iron (III) hydroxide were converted into 
magnetite by hydrothermal treatment in an aqueous solution containing ethyleneglycol 
and urea.[6] In the present study, magnetite microspheres were obtained without further 
thermal or hydrothermal treatments. Based on the present results, this streamlined 
fabrication process is effective. Magnetite nanoparticles can easily aggregate in aqueous 
conditions through van der Waals and weak magnetic attractions.[13] The present 
microspheres are assumed to be constructed by dehydration and aggregation of the 
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7magnetite nanoparticles in butanol. Because the prepared microspheres were not broken 
after being shaken in ultrapure water (Fig. 3), they are expected to have a low risk of 
injuring the surrounding blood vessels in vivo caused by broken fragments. The high 
aggregation potential of the magnetite nanoparticles likely contributes to the high 
mechanical integrity of the microspheres. 
The prepared microspheres were able to incorporate and release alendronate, and 
that release rate was controlled by the alendronate concentration. Iron oxide and 
phosphate can construct a complex via formation of an Fe-O-P bond.[14] Therefore, the 
phosphate group of the alendronate may construct a similar complex with magnetite 
crystals as shown schematically in Figure 7. The released portion of alendronate from 
the microspheres after 7 days was estimated to be 8% based on the results in Figures 4 
and 5. Tight bonding between the magnetite and the alendronate would contribute to the 
prevention of an initial burst and increase continuous drug release. 
The release of bisphosphonate from hydroxyapatite-based microparticles has been 
reported by several research groups. Seshima et al. investigated the release of 
pamidronate, a type of bisphosphonate, from calcined hydroxyapatite granules of 
300–500 µm in diameter.[15] After soaking the granules calcined at 400°C for 3 days, 
the pamidronate concentration was 0.3 mM and the survival rate of osteoclasts was 
decreased to 40%. This indicates that bone resorption can be suppressed by pamidronate 
release. 
In addition, Shi et al. prepared composite microspheres of poly(DL-lactic 
acid-co-glycolic acid) and hydroxyapatite, incorporated alendronate through emulsion 
methods, and examined its release behavior.[16] After 3 days, the alendronate 
concentration was 5.4 µM, but there was no significant change in osteoblast 
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8proliferation compared with negative controls. Conversely, after 7 days, the 
concentration had increased to 8.6 µM and significant osteoblast proliferation was 
observed. 
Although the surface area of the magnetite microspheres (82.3 m
2
/g) prepared in
the present study was larger than that of the hydroxyapatite prepared by Seshima et al. 
(46.2 m
2
/g), the mass of released alendronate after 3 days (1.5 µM at maximum) was
smaller than that reported in the above two papers. This might be attributed to a smaller 
powder to liquid ratio in the drug release measurement. In addition, magnetite is likely 
more positively charged than hydroxyapatite because the isoelectric point of the former 
(6.5) is higher than that of the latter (6.0).[17, 18] Thus, the tight ionic attraction of the 
magnetite with the negatively charged alendronate may also contribute to the slower 
release. However, further increasing the alendronate concentration loaded in the 
microspheres may increase the release up to the level necessary for effective 
enhancement of bone formation. 
Porous magnetite microspheres were prepared using emulsion methods. These 
microspheres showed slow release of alendronate, a bisphosphonate drug. The release 
rate could be well controlled by the drug concentration loaded into the microspheres. 
The microspheres were able to release the drug over a long time and are therefore useful 
for novel hyperthermia and chemotherapy combined treatments. 
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Figure legends 
Figure 1: SEM image of the prepared microspheres. 
Figure 2: XRD pattern of the prepared microspheres. 
Figure 3: SEM image of the prepared microspheres after being shaken in ultrapure 
water for 3 days. 
Figure 4: Mass of alendronate incorporated into the microspheres as a function of the 
solution alendronate concentration. 
Figure 5: Alendronate concentration after soaking drug-loaded microspheres in 
ultrapure water over time as a function of the initial alendronate concentration. 
Figure 6: Alendronate concentration after soaking drug-loaded microspheres in 
ultrapure water plotted as a function of the square root of time for different initial 
alendronate concentrations. 
Figure 7: Schematic representation of binding of alendronate to magnetite. 
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